Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas
Verma, Nirmal; Velmurugan, Gopal Viswanathan; Winford, Edric; Coburn, Han; Kotiya, Deepak; Leibold, Noah; Radulescu, Laura; Despa, Sanda; Chen, Kuey C.; Van Eldik, Linda J.; Nelson, Peter T.; Wilcock, Donna M.; Jicha, Gregory A.; Stowe, Ann M.; Goldstein, Larry B.; Powel, David K.; Walton, Jeffrey H.; Navedo, Manuel F.; Nystoriak, Matthew A.; Murray, Andrew J.; Biessels, Geert Jan; Troakes, Claire; Zetterberg, Henrik; Hardy, John; Lashley, Tammaryn; Despa, Florin
(2023) Communications biology, volume 6, issue 1
(Article)
Abstract
Impairment of vascular pathways of cerebral β-amyloid (Aβ) elimination contributes to Alzheimer disease (AD). Vascular damage is commonly associated with diabetes. Here we show in human tissues and AD-model rats that bloodborne islet amyloid polypeptide (amylin) secreted from the pancreas perturbs cerebral Aβ clearance. Blood amylin concentrations are higher in
... read more
AD than in cognitively unaffected persons. Amyloid-forming amylin accumulates in circulating monocytes and co-deposits with Aβ within the brain microvasculature, possibly involving inflammation. In rats, pancreatic expression of amyloid-forming human amylin indeed induces cerebrovascular inflammation and amylin-Aβ co-deposits. LRP1-mediated Aβ transport across the blood-brain barrier and Aβ clearance through interstitial fluid drainage along vascular walls are impaired, as indicated by Aβ deposition in perivascular spaces. At the molecular level, cerebrovascular amylin deposits alter immune and hypoxia-related brain gene expression. These converging data from humans and laboratory animals suggest that altering bloodborne amylin could potentially reduce cerebrovascular amylin deposits and Aβ pathology.
show less
Download/Full Text
Keywords: Medicine (miscellaneous), General Biochemistry,Genetics and Molecular Biology, General Agricultural and Biological Sciences
ISSN: 2399-3642
Publisher: Springer Nature
Note: Funding Information: Funding in part by: University of Kentucky Research Alliance to Reduce Diabetes-Associated Microvascular Dysfunction (ADAM) and National Institutes of Health R01 NS116058, R01 AG057290, R01 AG053999, R01 HL 149127 and P30 AG028383, and Alzheimer’s Association VMF-15-363458. UK Dementia Research Institute which receives its funding from DRI Ltd, funded by: the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK; Medical Research Council (award number MR/N026004/1); Wellcome Trust Hardy (award number 202903/Z/16/Z); Dolby Family Fund; National Institute for Health Research University College London Hospitals Biomedical Research Center; BRCNIHR Biomedical Research Center at University College London Hospitals NHS Foundation Trust and University College London. H.L. was supported by an American Heart Association fellowship (18PRE33990154). T.L. is supported by an Alzheimer’s Research UK Senior Fellowship. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). Publisher Copyright: © 2023, The Author(s).
(Peer reviewed)